Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MobiSCD: High-Dose Plerixafor for Stem Cell Mobilization in Sickle Cell Disease
NCT07341022Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Drugs
- plerixafor
- Conditions
- sickle cell disease (SCD)
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in sickle cell disease (SCD), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: CD34+ cell count at 0 days. Planned start Jun 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Arm A: high-dose plerixafor
480 mcg/kg plerixafor single dose
03
Who it enrols
Patients aged 18-25 with sickle cell disease, adequate organ function, and indication for allogeneic HSCT, excluding those with recent hospitalizations, prior transplants, or active infections.
04
Endpoints
Primary
CD34+ cell count
Beyond the preview
Go deeper on NCT07341022.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341022.